Leishmania major-derived peptides KMP11 and GP63 computationally identified as non-toxic anticancer candidates
Background
The discovery of novel anticancer peptides (ACPs) is crucial for developing new therapeutic strategies, as current cancer treatments often face challenges like drug resistance and systemic toxicity. ACPs offer promise due to their selective cytotoxicity against cancer cells, often by disrupting cell membranes or modulating intracellular pathways. However, systematic identification of effective and safe ACPs, especially from diverse biological sources like parasitic proteins, remains a significant bioinformatics challenge, requiring robust computational frameworks to predict efficacy and minimize off-target effects.
Study Design
Researchers developed an integrated bioinformatics pipeline to identify anticancer peptide candidates from Leishmania major proteins KMP11 and GP63. Peptide fragments, ranging from 5 to 25 residues, were computationally generated and initially screened using AntiCP 2.0 and MLACP prediction tools. Candidate peptides underwent systematic amino acid substitutions and iterative re-evaluation for optimized anticancer properties. Safety assessments included TOXINPRED2 for toxicity, ALGPRED2 for allergenicity, and VAXIJEN2 for antigenicity. Prioritization of peptides meeting criteria was performed using the TOPSIS multi-criteria decision-making model. Structural modeling, exploratory molecular docking against selected cancer-associated receptors, and coarse-grained membrane interaction analyses were also conducted.
Results
The integrated bioinformatics framework successfully identified novel anticancer peptide candidates. Motif analysis, using MERCI on reference datasets, revealed sequence patterns associated with anticancer activity, with enriched motifs most frequently observed in the 12-13 residue range. > Following iterative screening and safety evaluation, specific subsets of peptides derived from KMP11 and GP63 were identified as non-toxic and non-allergenic based on in silico predictions. These promising peptides were subsequently prioritized using the TOPSIS model. The top-ranked candidates demonstrated favorable membrane interaction profiles and potential accessibility to cancer-associated receptors through exploratory molecular docking, suggesting potential mechanisms of action without predicting specific binding.
Why It Matters
This study provides a novel computational pipeline for discovering anticancer peptides from unconventional sources like parasitic proteins, potentially accelerating early-stage drug discovery. Identifying non-toxic, non-allergenic peptide candidates from Leishmania major opens new avenues for developing targeted cancer therapies. While these are currently in silico predictions, the methodology offers a systematic approach to prioritize candidates for future experimental validation. This work doesn't immediately impact current clinical protocols but lays foundational groundwork for future peptide drug development, potentially leading to new therapeutic agents with improved safety profiles.